The warrant exercise price adjustment is a mechanical consequence of ATM sales, not a new catalyst. Monitor the company's next 10-Q for updated share count and cash position to assess ongoing dilution from the ATM program.
Price Chart
Executive Summary
Sunshine Biopharma disclosed that recent sales under its at-the-market (ATM) offering triggered an automatic reduction in the exercise price of its outstanding Series B Warrants to $1.2202. This is a routine administrative disclosure tied to ongoing equity dilution, with no new financial data or material operational update provided.
Key Facts
- Exercise price of Series B Warrants reduced to $1.2202 due to recent ATM common stock sales
- Warrant exercise price subject to further adjustment per warrant terms
- No financial figures, revenue, earnings, or guidance disclosed in the filing
Financial Impact
Warrant exercise price adjustment only — no new capital raise, cash flow, or financial results disclosed
Risk Factors
- Continued ATM sales will further dilute common shareholders and may push the warrant exercise price lower
- Micro-cap biotech with $2M market cap faces elevated financing and delisting risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001683168-26-005899 |
| Document: 0001683168-26-005899-index-headers.html | 0001683168-26-005899 |
| Document: 0001683168-26-005899-index.html | 0001683168-26-005899 |
| Document: 0001683168-26-005899.txt | 0001683168-26-005899 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 13d ago | SC 13G | $0.2430 $0.2154 | ▼ −11.36% | ▼ −11.81% | $2.96 (+1118.11%) |
Oct 13, 2026 14d ago | SC 13G | $0.2430 $0.2154 | ▼ −11.36% | ▼ −11.81% | $2.96 (+1118.11%) |
Oct 9, 2026 18d ago | 8-K | $0.3020 $0.2418 | ▲ +19.93% | ▲ +18.44% | $2.96 (−880.13%) |
Oct 9, 2026 18d ago | 424B4 | $0.3020 $0.2418 | ▲ +19.93% | ▲ +18.44% | $2.96 (−880.13%) |
Oct 8, 2026 20d ago | EFFECT | $0.4300 $0.2300 | ▲ +46.51% | ▲ +46.24% | $2.96 (−588.37%) |
Oct 5, 2026 22d ago | SC 13G/A | $0.3979 $0.2363 | ▲ +40.61% | ▲ +40.47% | $2.96 (−643.91%) |
Oct 2, 2026 25d ago | S-1 | $0.4201 $0.3020 | ▲ +28.11% | ▲ +28.53% | $2.96 (−604.59%) |
Sep 9, 2026 7w ago | EFFECT | $1.12 $1.04 | ▲ +7.59% | ▲ +7.26% | $2.96 (−164.29%) |
Aug 28, 2026 8w ago | 8-K | $1.12 $1.15 | ▲ +2.68% | ▲ +2.82% | $2.96 (+164.29%) |
Aug 3, 2026 12w ago | 8-K | $23.40 $24.40 | ▲ +4.27% | ▲ +2.25% | $2.96 (−87.35%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers